Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Return on Assets (2018 - 2019)

Historic Return on Assets for Monopar Therapeutics (MNPR) over the last 3 years, with Q3 2020 value amounting to 0.08%.

  • Monopar Therapeutics' Return on Assets rose 6700.0% to 0.08% in Q3 2020 from the same period last year, while for Sep 2020 it was 0.08%, marking a year-over-year increase of 6700.0%. This contributed to the annual value of 0.42% for FY2019, which is 400.0% down from last year.
  • As of Q3 2020, Monopar Therapeutics' Return on Assets stood at 0.08%, which was up 6700.0% from 0.15% recorded in Q2 2020.
  • Monopar Therapeutics' 5-year Return on Assets high stood at 0.08% for Q3 2020, and its period low was 1.96% during Q2 2018.
  • Moreover, its 3-year median value for Return on Assets was 0.47% (2019), whereas its average is 0.67%.
  • Data for Monopar Therapeutics' Return on Assets shows a peak YoY increase of 13000bps (in 2019) and a maximum YoY decrease of -3900bps (in 2019) over the last 5 years.
  • Over the past 3 years, Monopar Therapeutics' Return on Assets (Quarter) stood at 0.42% in 2018, then decreased by -13bps to 0.47% in 2019, then soared by 83bps to 0.08% in 2020.
  • Its last three reported values are 0.08% in Q3 2020, 0.15% for Q2 2020, and 0.22% during Q1 2020.